Phase 3 N=70 Randomized Single-blind Prevention

Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries

Hypertension · Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00829296 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2014

Primary outcome: Primary: Change in Central Systolic Blood Pressure (SBP) — 125.3; 127.8; 121.6; 123.8 mmHg

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: nebivolol (Drug); Metoprolol (Drug)
Age: Adult, Older Adult · 50+ yrs
Sex: All
Sponsor: University of Chicago
Primary completion: Apr 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Central Systolic Blood Pressure (SBP)	125.3; 127.8; 121.6; 123.8	—
SECONDARY Change in Pulse Wave Velocity (PWV)	6.48; 6.52; 6.3; 6.4	—
SECONDARY Change in Augmentation Index	22.0; 26.2; 22.1; 24.6	—
SECONDARY Change in Pulse Pressure Amplification	0.77; 0.79; 0.83; 0.85	—

Summary

The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.

Eligibility Criteria

Inclusion Criteria

Established Type 2 diabetic not treated with insulin
Stage 1 hypertensives blood pressure > 130/80 mmHg and 160mmHg or diastolic blood pressure > 100 mmHg

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00829296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.